Clene swings to $3.9 million Q3 net income on warrant gains; ALS drug application filed
Clene reported third quarter 2026 net income of $3.9 million, or $0.05 per diluted share, compared with a net loss of $8.8 million, or $0.85 per share, a year earlier. The company said the swing came mainly from non-operating fair value gains on warrant and derivative liabilities, while its operating loss widened to $6.3 million from $5.6 million. The company also submitted a New Drug Application for CNM-Au8 in ALS in October and said its cash runway extends to mid-first quarter 2027.
Key points
- Net income of $3.9 million for the quarter ended September 30, 2026, versus a net loss of $8.8 million a year earlier; total other income was $10.3 million, mainly from fair value changes in warrant and derivative liabilities
- Loss from operations was $6.3 million, up from $5.6 million; research and development expenses rose to $4.4 million from $3.5 million
- Cash and cash equivalents totaled $9.9 million at September 30, 2026; a $4.0 million registered direct offering in September is expected to fund operations through mid-first quarter 2027
- NDA for CNM-Au8 submitted to the FDA in October 2026 seeking accelerated approval for ALS; Phase 3 RESTORE-ALS trial planned to start in the second quarter of 2027
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.